Skip to navigation

Management Team

 

Charles M. Baum, MD, PhD

President and CEO

ChuckBaum

Dr. Baum was appointed President and Chief Executive Officer and Board Member of Mirati Therapeutics in November 2012. Since then, he has been responsible for moving the company to the United States, listing the company on NASDAQ and establishing its headquarters in San Diego, California. In addition, he has built a world class precision oncology leadership team and transformed Mirati into a company focused on the innovative, targeted development of Mirati’s receptor tyrosine kinase and histone deacetylase inhibitors in various cancers.

Prior to joining Mirati he was Senior Vice President for Biotherapeutic Clinical Research within Pfizer’s Worldwide Research & Development division. Dr. Baum was at Pfizer from 2003 until joining Mirati in 2012, serving in roles of increasing responsibility including as Vice President and Head of Oncology Development and as Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. He was responsible for the development of the oncology portfolio, including Axitinib (Inlyta®), Crizotinib (Xalkori®) and the approval of sunitinib (Sutent®) for the treatment of gastrointestinal stromal tumor (GIST) and renal cell carcinoma. Prior to joining Pfizer, Dr. Baum was responsible for the Phase I-IV development of several oncology compounds at Schering-Plough, including temozolomide (Temodar®) which was approved for the treatment of patients with advanced brain tumors.

His career has included academic and hospital positions at Stanford and Emory universities, as well as positions of increasing responsibility within the pharmaceutical industry (Systemix, Searle, Schering-Plough and Pfizer). Dr. Baum currently serves on the board of directors of Array BioPharma. Dr. Baum received his M.D. and Ph.D. (Immunology) degrees from Washington University School of Medicine in St. Louis, Missouri and completed his post-graduate training at Stanford University, California. Dr. Baum has received research support from the National Institutes of Health and the American Cancer Society, published more than 50 peer-reviewed manuscripts, and holds a number of patents and patent applications.

Isan Chen, MD

Chief Medical and Development Officer

image

Isan Chen, MD is board certified in internal medicine, hematology and medical oncology with more than 15 years of experience in oncology and clinical trials from first-in-humans through global studies designed to support regulatory registration. He has experience in oncology clinical development and interactions with regulatory agencies in the US and Europe. He was most recently the Chief Medical Officer of Aragon Pharmaceuticals which was acquired by Johnson & Johnson in July of 2013. At Aragon, Dr. Chen was responsible for the clinical development strategy of all the company’s programs, including prostate and breast cancer. Prior to Aragon, Dr. Chen served as Vice President of Tumor Strategy in the oncology business unit at Pfizer. In addition he was the clinical lead for sunitinib (Sutent®), a multiple kinase inhibitor, for the treatment of renal cell carcinoma, an indication in which the drug secured FDA approval in 2006. He was also the clinical lead for the Phase I studies of crizotinib (Xalkori®) and CDK 4/6 inhibitor palbociclib.

Dr. Chen completed his hematology/oncology fellowship at University of California, San Diego. Before joining Pfizer, Dr. Chen practiced medicine as a staff physician at City of Hope Medical Center and later as an assistant professor at the University of Texas, M.D. Anderson Cancer Center.

James Christensen, PhD

Senior Vice President & Chief Scientific Officer

image

Dr. Christensen joined Mirati in June 2013. He was most recently the Senior Director of Oncology Precision Medicine in the Oncology Research Unit at Pfizer, a group focused on developing strategies toward patient identification, novel combination approaches, and development of biomarker approaches. Dr. Christensen joined Pfizer in 2003 and his responsibilities there included leading nonclinical research efforts for oncology programs including sunitinib (Sutent®) research activities and leading the nonclinical and translational biology efforts for other research and development programs including crizotinib (Xalkori®). Dr. Christensen participated as a member of the Pfizer Cancer Research or Oncology Research Unit leadership team from 2005-2013. Prior to 2003, Dr. Christensen was at SUGEN/Pharmacia as a Group Leader on the Preclinical Research and Exploratory Development team where he was responsible for leadership of c-Met and erbB family preclinical development programs and aspects of research and development for sunitinib. Dr. Christensen initiated his industry experience at Warner Lambert/Parke-Davis with research focus in receptor tyrosine kinase (RTK) biology and RTK pathway biomarker development in the oncology therapeutic area. Dr. Christensen has authored or co-authored over 100 peer-reviewed research articles in scientific journals including Science, Nature, Cancer Cell, New England Journal of Medicine and others. In addition, Dr. Christensen participates on the editorial boards for Cancer Research and Molecular Cancer Therapeutics.

Dr. Christensen received his PhD degree focusing in Molecular Pharmacology from North Carolina State University with dissertation research directed toward characterization of mechanisms of apoptosis dysregulation during the process of carcinogenesis.

Chris LeMasters

Executive Vice President and Chief Business Officer

image

Mr. LeMasters joined Mirati in October 2016. Prior to joining Mirati, Mr. LeMasters served as the CEO of Promosome, a privately held biotherapeutics and synthetic biology company. Previously, Mr. LeMasters held senior management positions at several biotherapeutics companies, most recently as co-founder and chief business officer of Tragara Pharmaceuticals, a clinical-stage cancer therapeutics company. Mr. LeMasters also served as co-founder and chief business officer of Cabrellis Pharmaceuticals, Inc., where he negotiated its acquisition by Pharmion Corporation for $104 million, and as vice president, corporate development of Conforma Therapeutics, where he negotiated its acquisition by Biogen IDEC for $250 million. Mr. LeMasters also worked in the corporate business development group at Eli Lilly & Company and was responsible for the successful negotiation of numerous partnerships and licenses across a range of therapeutic areas. Earlier in his career, he was a management consultant with Coopers & Lybrand Consulting and an operational auditor with Owens Corning. Mr. LeMasters currently serves as a board member of Aarden Pharmaceuticals, where he is also a co-founder, and as a board member of the Hoosier Cancer Research Network, a clinical research organization. He received a B.S. degree in Finance from Indiana University and an MBA with honors from the University of Chicago

Jamie Donadio

Senior Vice President and Chief Financial Officer

image

Mr. Donadio joined Mirati in March 2013. From April 2001 to January 2013, Mr. Donadio held a number of corporate finance and accounting positions at Amylin Pharmaceuticals, Inc., most recently serving as Senior Director of Finance with responsibility for corporate finance activities including financial planning and analysis, treasury and capital formation strategy. Previously at Amylin, Mr. Donadio was responsible for the company’s SEC reporting and has extensive working knowledge of public company accounting and reporting matters. From December 2000 to April 2001 Mr. Donadio was Senior Accountant at Novatel Wireless, Inc. From August 1997 to December 2000 Mr. Donadio was with Ernst & Young LLP, last serving as an audit senior.

Mr. Donadio holds a B.S. in accounting from Babson College and is a certified public account (inactive) in the State of California.

Marcy Graham

Vice President, Investor Relations and Corporate Communications

Our Team - Marcy Graham

Marcy Graham joined Mirati in January of 2016 as Vice President, Investor Relations and Corporate Communications. She had previously served as Vice President, Investor Relations and Corporate Communications at aTyr Pharma, taking them through their IPO in 2015. Previously, Ms. Graham served as Head of Investor Relations and Corporate Communications at Ambit Biosciences, a biopharmaceutical company, until their acquisition by Daichi Sankyo in late 2014. Before joining Ambit, Ms. Graham served as Senior Director, Investor Relations and Corporate Communications at Sequenom, Inc., a life sciences diagnostics company. She joined Genoptix, Inc. at their IPO in 2007 as the Executive Director, Investor Relations, serving until their acquisition by Novartis in 2011. Her previous experience includes oversight of Investor Relations at Novatel Wireless following a position heading the Investor Relations effort at Leap Wireless, home of wireless telecommunications provider Cricket Communications.

Ms. Graham holds a Certification in Investor Relations from the University of California, Irvine, an M.B.A. from the Robert O. Anderson School of Management at the University of New Mexico and a B.A. degree in Journalism and Mass Communications from the University of New Mexico.

Dennis M. Hester, PhD

Vice President, Product Development and Head of CMC

image

Dr. Hester was appointed Vice President, Product Development and Head of CMC in July 2014 after building a CMC team and serving as Executive Director, Product Development and Head of CMC from September 2013.  Dr. Hester has over twenty years of experience in the development of large and small molecules working with a number of development platforms including solid/liquid oral, inhalation and parenteral technologies.  Most recently, he served as Senior Director, Pharmaceutical Sciences at Aragon Pharmaceuticals working on ARN-509, for prostate cancer, which was acquired by Johnson & Johnson in July of 2013 and ARN-810, for Breast Cancer, with was acquired by Genentech in July 2014.   Prior to Aragon, Dr. Hester was Director, Pharmaceutical Development at Intellikine working on kinase inhibitors INK-128 and INK-1117 which were acquired by Takeda in January of 2012.  Prior to Intellikine, Dr. Hester held leadership roles in two San Diego biotech startups.  From March 2003 to October 2006, Dr. Hester was Associate Director, Product Development at Amylin Pharmaceuticals responsible for CMC development activities that ultimately led to the commercialization of Bydureon®, a once weekly extended-release parenteral suspension for the treatment of Type 2 diabetes.  Prior to Amylin, between December 1999 and March 2003, he was a CMC Lead working on inhalation technologies for various therapeutic indications at Nektar Therapeutics (formerly Inhale Therapeutics).  Dr. Hester started his career at Zeneca where he was a product development Scientist/Sr. Scientist from October 1992 to August 1999.

Dr. Hester holds a Ph.D. in Physical Chemistry from the University of Southern California, an ACS Accredited B.S. in Chemistry from the United States Air Force Academy and is an inventor on six U.S. patents.

Perry C. Johnston

Vice President, Chief Legal and Compliance Officer, and Corporate Secretary

image

Mr. Johnston joined Mirati as an employee in February 2014, having previously supported the company in a consulting capacity commencing in July 2013. With more than twenty years of in-house experience, Mr. Johnston has served on senior leadership teams and helped build and lead legal, compliance, regulatory and risk management functions. From August 2009 to July 2013, Mr. Johnston served as Senior Director of Legal at Amylin Pharmaceuticals, Inc. where he led the Transactions/Contracts Group and managed legal support for the Corporate Development, Business Development, and Alliance Management functions. Prior to joining Amylin, Mr. Johnston served in senior leadership roles with various biotechnology, health provider, and medical device companies, including as Vice President, General Counsel and Company Secretary at Advanced BioEnergy LLC, Vice President of Legal, Regulatory and Compliance at Aperio Technologies, Inc., Vice President, General Counsel and Corporate Secretary at the Nevada Cancer Institute, Vice President of Legal and Compliance at CardioNet, Inc., and Senior Legal Counsel at Medtronic, Inc. Mr. Johnston worked as an attorney in private practice for several years and began his career after law school in the tax field, working with both Coopers & Lybrand in Minneapolis and KPMG Peat Marwick in San Diego.

Mr. Johnston received his Juris Doctor degree from the University of Minnesota Law School and his B.S. Business Administration (finance and economics emphasis) from the University of Minnesota School of Management.

Bydureon® is a registered trademark of Amylin Pharmaceuticals, Inc.
Temodar® is a registered trademark of Merck & Co., Inc.
Xalkori®, Inlyta® and Sutent® are registered trademarks of Pfizer, Inc.